AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6207731 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon treatment for adenoviral conjunctivitis
Number of subjects: 14
Study 6207731 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for adenoviral conjunctivitis
Number of subjects: 14
Study 31433462 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Number of subjects: 0
Study 31433462 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 30036516 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate 20 mEq twice daily
Number of subjects: 13
Study 30036516 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid 30 mEq twice daily
Number of subjects: 13
Study 30036516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27004284 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched rough collar (PSRC)
Number of subjects: 26
Study 27004284 — intervention group
Group type: COMPARATOR
Intervention: Platform-matched smooth collar (PMSC)
Number of subjects: 26
Study 24472731 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 49
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 30 mg/kg BW
Number of subjects: 16
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 60 mg/kg BW
Number of subjects: 16
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 90 mg/kg BW
Number of subjects: 16
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 150 mg/kg BW
Number of subjects: 16
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 300 mg/kg BW
Number of subjects: 16
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 450 mg/kg BW
Number of subjects: 16
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 14 mg/kg BW
Number of subjects: 16
Study 22205670 — intervention group
Group type: COMPARATOR
Intervention: Sodium chlorate 42 mg/kg BW
Number of subjects: 16
Study 21038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist structure with high patient reactance
Number of subjects: 127
Study 21038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist structure with low patient reactance
Number of subjects: 127
Study 21038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to therapeutic work
Number of subjects: 127
Study 17332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal A (500-ml 15% oil emulsion with 2.5% stable emulsifier)
Number of subjects: 9
Study 17332474 — intervention group
Group type: COMPARATOR
Intervention: Meal B (500-ml 15% oil emulsion with 2.5% unstable emulsifier)
Number of subjects: 9
Study 15025217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated hydrogen peroxide-based mouthrinse
Number of subjects: 99
Study 15025217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 11486635 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin + 50 mg caffeine
Number of subjects: 96
Study 11486635 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin + 100 mg caffeine
Number of subjects: 96
Study 11486635 — intervention group
Group type: COMPARATOR
Intervention: 0 mg aspirin + 0 mg caffeine
Number of subjects: 96
Study 11486635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg aspirin + 50 mg caffeine
Number of subjects: 96
Study 11486635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg aspirin + 100 mg caffeine
Number of subjects: 96
Study 11486635 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin alone
Number of subjects: 96
Study 11486635 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin + caffeine (any dosage)
Number of subjects: 96
Study 9923583 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg t.i.d. and ethanol placebo
Number of subjects: 30
Study 9923583 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg t.i.d. and 40 g ethanol qd on days -1 and 6, and 40 g bid on days 1-5
Number of subjects: 30
Study 9923583 — intervention group
Group type: COMPARATOR
Intervention: orlistat placebo tid and 40 g ethanol qd on days -1 and 6, and 40 g b.i.d. on days 1-5
Number of subjects: 30
Study 7846204 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine decanoate (PD)
Number of subjects: 29
Study 7846204 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol decanoate (HD)
Number of subjects: 29
Study 3288957 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program with caloric restriction and behavior change (n = 26)
Number of subjects: 72
Study 3288957 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program with caloric restriction, behavior change, and exercise (n = 25)
Number of subjects: 72
Study 3288957 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program with exercise
Number of subjects: 72
Study 30609278 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping plus exercises (n=10)
Number of subjects: 30
Study 30609278 — intervention group
Group type: COMPARATOR
Intervention: Sham taping plus exercises (n=10)
Number of subjects: 30
Study 30609278 — intervention group
Group type: COMPARATOR
Intervention: Exercises only (n=10)
Number of subjects: 30
Study 29624723 — intervention group
Group type: EXPERIMENTAL
Intervention: RT001 (1.8 or 9.0 g/day)
Number of subjects: 19
Study 29624723 — intervention group
Group type: COMPARATOR
Intervention: Nondeuterated ethyl linoleate (control)
Number of subjects: 19
Study 26511775 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based training on two procedures (appendicectomy followed by salpingectomy)
Number of subjects: 96
Study 26511775 — intervention group
Group type: COMPARATOR
Intervention: Control group (training on one procedure - salpingectomy)
Number of subjects: 96
Study 24660674 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM) intervention (CBT, medication, or both)
Number of subjects: 336
Study 24660674 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study 22561876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 502
Study 22561876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 20632490 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous PRP gel with acellular xenogeneic dermal matrix (PRP group)
Number of subjects: 30
Study 20632490 — intervention group
Group type: COMPARATOR
Intervention: Acellular xenogeneic dermal matrix only (control group)
Number of subjects: 30
Study 17547800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg) intra-arterially before PCI, with a possible supplement of 0.3 mg/kg if procedural time > 90 minutes.
Number of subjects: 160
Study 17547800 — intervention group
Group type: COMPARATOR
Intervention: UFH (100 U/kg) intra-arterially before PCI.
Number of subjects: 160
Study 16339330 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise activity group (n = 13)
Number of subjects: 28
Study 16339330 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group (n = 15)
Number of subjects: 28
Study 12228782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy before planned angioplasty
Number of subjects: 0
Study 12228782 — intervention group
Group type: COMPARATOR
Intervention: Direct angioplasty
Number of subjects: 0
Study 10190761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% naproxen ophthalmic solution
Number of subjects: 12
Study 10190761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% naproxen ophthalmic solution
Number of subjects: 12
Study 10190761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8544422 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril test
Number of subjects: 82
Study 1703608 — intervention group
Group type: EXPERIMENTAL
Intervention: D + HCTZ (dilevalol + hydrochlorothiazide)
Number of subjects: 61
Study 1703608 — intervention group
Group type: COMPARATOR
Intervention: C + HCTZ (captopril + hydrochlorothiazide)
Number of subjects: 61
Study 380340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable erythrityl tetranitrate, 10 mg
Number of subjects: 7
Study 380340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31486844 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy mask worn for a minimum of 4 hours after dilating drop instillation
Number of subjects: 51
Study 31486844 — intervention group
Group type: COMPARATOR
Intervention: Standard comfort measures (Control group)
Number of subjects: 51
Study 27572248 — intervention group
Group type: EXPERIMENTAL
Intervention: L-selenomethionine 166 µg/die
Number of subjects: 76
Study 27572248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26052984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671
Study 26052984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study 24750973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-month recall notification
Number of subjects: 10175
Study 24750973 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month reminder notification
Number of subjects: 10175
Study 24750973 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-month recall notification
Number of subjects: 10175
Study 24750973 — intervention group
Group type: COMPARATOR
Intervention: No notification
Number of subjects: 10175
Study 22683257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (Antox version 1.2, Pharma Nord, Morpeth, UK)
Number of subjects: 70
Study 22683257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets, 3 times/day)
Number of subjects: 70
Study 19056596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with supplemental virgin olive oil (VOO)
Number of subjects: 112
Study 19056596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with supplemental nuts
Number of subjects: 112
Study 19056596 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 112
Study 17634457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with an antiplatelet agent and an oral anticoagulant agent (target INR, 2.0 to 3.0)
Number of subjects: 2161
Study 17634457 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 2161
Study 15013302 — intervention group
Group type: COMPARATOR
Intervention: Femoral loop grafts (group I)
Number of subjects: 32
Study 15013302 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral vein transposition (group II)
Number of subjects: 32
Study 12209041 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 5 mg q.d.
Number of subjects: 617
Study 12209041 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 10 mg q.d.
Number of subjects: 617
Study 12209041 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 30 mg q.d.
Number of subjects: 617
Study 12209041 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 60 mg q.d.
Number of subjects: 617
Study 12209041 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 90 mg q.d.
Number of subjects: 617
Study 12209041 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg q.d. (Part 2)
Number of subjects: 617
Study 12209041 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg q.d. (Part 2)
Number of subjects: 617
Study 12209041 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg q.d. (Part 2)
Number of subjects: 617
Study 12209041 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg t.i.d. (Part 2)
Number of subjects: 617
Study 9825197 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 18
Study 9825197 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (100 mg b.i.d.)
Number of subjects: 18
Study 9825197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg b.i.d.)
Number of subjects: 18
Study 9825197 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg b.i.d.)
Number of subjects: 18
Study 9825197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 18
Study 9825197 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil, Diltiazem, Verapamil
Number of subjects: 18
Study 7650225 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (30-minute infusion at 3 dose levels: 600, 1200, and 2000 mg/m2)
Number of subjects: 14
Study 7650225 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate
Number of subjects: 14
Study 7650225 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylacetate
Number of subjects: 14
Study 7650225 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylacetylglutamine
Number of subjects: 14
Study 7650225 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate, phenylacetate, and phenylacetylglutamine
Number of subjects: 14
Study 2655248 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (TV)
Number of subjects: 248
Study 2655248 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy and drainage (SV)
Number of subjects: 248
Study 2655248 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 248
Study 2655248 — intervention group
Group type: COMPARATOR
Intervention: All groups (TV, SV, PCV)
Number of subjects: 248
Study 217894 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG 2250 mg per day
Number of subjects: 36
Study 217894 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG 3000 mg per day
Number of subjects: 36
Study 217894 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG 2250 mg and 3000 mg per day
Number of subjects: 36
Study 217894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31582355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg for 30 min every 2 weeks)
Number of subjects: 419
Study 31582355 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel 100 mg/m2 once per week for 6 weeks or docetaxel 75 mg/m2 every 3 weeks)
Number of subjects: 419
Study 31582355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 419
Study 31582355 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 419
Study 28973315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor treatment
Number of subjects: 67
Study 26255043 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in FODMAPs (n=38)
Number of subjects: 75
Study 26255043 — intervention group
Group type: COMPARATOR
Intervention: Traditional IBS diet (n=37)
Number of subjects: 75
Study 23422332 — intervention group
Group type: EXPERIMENTAL
Intervention: Radix Astragali extract granules (4g bid for 7 days)
Number of subjects: 14
Study 23422332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4g bid for 7 days)
Number of subjects: 14
Study 23422332 — intervention group
Group type: COMPARATOR
Intervention: ABCB1 3435T mutation allele carriers (placebo phase)
Number of subjects: 14
Study 23422332 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 3435CC carriers (RA extract phase)
Number of subjects: 14
Study 17086091 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg orally at bedtime for 6 weeks
Number of subjects: 47
Study 17086091 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg orally at bedtime for 6 weeks
Number of subjects: 47
Study 17086091 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 healthy subjects, no drug administration)
Number of subjects: 47
Study 15276658 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Beck Depression Inventory (CBDI) administered to all students
Number of subjects: 4143
Study 15276658 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary regression analysis
Number of subjects: 4143
Study 15276658 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms reported by adolescents with depression
Number of subjects: 4143
Study 11034630 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiation therapy with efficient fractionation schedules
Number of subjects: 0
Study 8798310 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cervical diathermy with fulgaration (RCDF)
Number of subjects: 55
Study 8798310 — intervention group
Group type: COMPARATOR
Intervention: Large loop excision of the transformation zone (LLETZ)
Number of subjects: 55
Study 8798310 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (LLETZ and RCDF)
Number of subjects: 55
Study 1351183 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group (n = 58): lactating mothers avoided allergenic foods (milk, egg, fish, and nuts) and avoided feeding their infants these foods and soya, wheat, and orange up to the age of 12 months; acaricidal treatment every 3 months.
Number of subjects: 120
Study 1351183 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 62): unrestricted diet for mothers and infants; no acaricidal treatment.
Number of subjects: 120
Study 1351183 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 62) for asthma prevalence.
Number of subjects: 120
Study 1351183 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 62) for eczema prevalence.
Number of subjects: 120
Study 3966504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and timed delivery
Number of subjects: 73
Study 3966504 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 73
Study 31694410 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring-guided strategy with VerifyNow P2Y12 test
Number of subjects: 1213
Study 31694410 — intervention group
Group type: EXPERIMENTAL
Intervention: HPR patients
Number of subjects: 1213
Study 31694410 — intervention group
Group type: COMPARATOR
Intervention: Non-HPR patients
Number of subjects: 1213
Study 27666156 — intervention group
Group type: COMPARATOR
Intervention: Steroid group (40mg of triamcinolone acetonide injected into the lateral epicondyle)
Number of subjects: 26
Study 27666156 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin tend group (20U of botulinum toxin injected into tender points of muscles)
Number of subjects: 26
Study 27666156 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin epic group (20U of botulinum toxin injection into the lateral epicondyle)
Number of subjects: 26
Study 25344944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABM
Number of subjects: 53
Study 25344944 — intervention group
Group type: COMPARATOR
Intervention: Placebo ABM
Number of subjects: 53
Study 25344944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 23750778 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote robotic catheter system (RCS)
Number of subjects: 45
Study 23750778 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 45
Study 20716383 — intervention group
Group type: EXPERIMENTAL
Intervention: Health visitor (HV) trained in identification and psychological intervention methods providing care based on cognitive behavioral or person-centered principles.
Number of subjects: 2241
Study 20716383 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving care as usual (CAU) from health visitors.
Number of subjects: 2241
Study 20716383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) women with a 6-week EPDS score of 6-11 (subthreshold subgroup).
Number of subjects: 2241
Study 20716383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) women with a 6-week EPDS score of 0-5 (lowest severity subgroup).
Number of subjects: 2241
Study 19888483 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 42
Study 19888483 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine
Number of subjects: 42
Study 16875978 — intervention group
Group type: EXPERIMENTAL
Intervention: NET inhibitor (sibutramine or reboxetine)
Number of subjects: 51
Study 16875978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12685057 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensities of oral anticoagulation (e.g., INR < 2.0) for long-term secondary prophylaxis of VTE
Number of subjects: 0
Study 12685057 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration LMWH therapy
Number of subjects: 0
Study 12685057 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antithrombotic agents
Number of subjects: 0
Study 10697082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated bone grafting
Number of subjects: 96
Study 10697082 — intervention group
Group type: COMPARATOR
Intervention: Pure cancellous bone grafting
Number of subjects: 96
Study 9379369 — intervention group
Group type: EXPERIMENTAL
Intervention: Divide and conquer phacoemulsification (D/C Group)
Number of subjects: 41
Study 9379369 — intervention group
Group type: COMPARATOR
Intervention: Chip and flip phacoemulsification (C/F Group)
Number of subjects: 41
Study 1370232 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair growth promoters
Number of subjects: 27
Study 1370232 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagen terminal scalp hairs
Number of subjects: 27
Study 1370232 — intervention group
Group type: COMPARATOR
Intervention: Indeterminate (anagen) hairs of balding scalps
Number of subjects: 27
Study 1370232 — intervention group
Group type: COMPARATOR
Intervention: Anagen follicles of vellus fore-arm hairs
Number of subjects: 27
Study 1370232 — intervention group
Group type: COMPARATOR
Intervention: Telogen scalp hairs
Number of subjects: 27
Study 1370232 — intervention group
Group type: COMPARATOR
Intervention: Telogen hairs of balding scalps
Number of subjects: 27
Study 1370232 — intervention group
Group type: COMPARATOR
Intervention: Telogen forearm hairs
Number of subjects: 27
Study 1370232 — intervention group
Group type: COMPARATOR
Intervention: Completely bald scalps
Number of subjects: 27
Study 3885472 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 30
Study 3885472 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 30